

Application No. 10/777,792  
Amendment dated June 2, 2006  
Reply to the Restriction Requirement of March 2, 2006

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-118. (Canceled).

119. (New) A pharmaceutical composition comprising A $\beta$ 1-7 linked to CRM197 to form a conjugate.

120. (New) The pharmaceutical composition of claim 119, wherein the conjugate comprises a plurality of additional copies of A $\beta$ 1-7.

121. (New) The pharmaceutical composition of claim 119, which comprises at least 10  $\mu$ g of A $\beta$ 1-7.

122. (New) The pharmaceutical composition of claim 119, which comprises at least 20  $\mu$ g of A $\beta$ 1-7.

123. (New) The pharmaceutical composition of claim 119, which comprises at least 50  $\mu$ g of A $\beta$ 1-7.

124. (New) The pharmaceutical composition of claim 119, which comprises at least 100  $\mu$ g of A $\beta$ 1-7.

125. (New) The pharmaceutical composition of claim 119, wherein A $\beta$ 1-7 is linked to CRM197 by chemical crosslinking.

126. (New) The pharmaceutical composition of claim 125, wherein the amino terminus of A $\beta$ 1-7 is linked to CRM197.

127. (New) The pharmaceutical composition of claim 125, wherein the carboxyl terminus of A $\beta$ 1-7 is linked to CRM197.

Application No. 10/777,792  
Amendment dated June 2, 2006  
Reply to the Restriction Requirement of March 2, 2006

128. (New) The pharmaceutical composition of claim 119, wherein the conjugate is expressed as a fusion protein.

129. (New) The pharmaceutical composition of claim 128, wherein the amino terminus of A $\beta$ 1-7 is linked to CRM197.

130. (New) The pharmaceutical composition of claim 128, wherein the carboxyl terminus of A $\beta$ 1-7 is linked to CRM197.

131. (New) A pharmaceutical composition comprising A $\beta$ 1-7 linked to CRM197 to form a conjugate and an adjuvant.

132. (New) The pharmaceutical composition of claim 131, wherein the conjugate comprises a plurality of additional copies of A $\beta$ 1-7.

133. (New) The pharmaceutical composition of claim 131, wherein the adjuvant comprises QS-21.

134. (New) The pharmaceutical composition of claim 133, which comprises at least 10  $\mu$ g of A $\beta$ 1-7.

135. (New) The pharmaceutical composition of claim 133, which comprises at least 20  $\mu$ g of A $\beta$ 1-7.

136. (New) The pharmaceutical composition of claim 133, which comprises at least 50  $\mu$ g of A $\beta$ 1-7.

137. (New) The pharmaceutical composition of claim 133, which comprises at least 100  $\mu$ g of A $\beta$ 1-7.

138. (New) The pharmaceutical composition of claim 133, wherein A $\beta$ 1-7 is linked to CRM197 by chemical crosslinking.

Application No. 10/777,792

Amendment dated June 2, 2006

Reply to the Restriction Requirement of March 2, 2006

139. (New) The pharmaceutical composition of claim 138, wherein the amino terminus of A $\beta$ 1-7 is linked to CRM197.

140. (New) The pharmaceutical composition of claim 138, wherein the carboxyl terminus of A $\beta$ 1-7 is linked to CRM197.

141. (New) The pharmaceutical composition of claim 133, wherein the conjugate is expressed as a fusion protein.

142. (New) The pharmaceutical composition of claim 141, wherein the amino terminus of A $\beta$ 1-7 is linked to CRM197.

143. (New) The pharmaceutical composition of claim 141, wherein the carboxyl terminus of A $\beta$ 1-7 is linked to CRM197.